AIM ImmunoTech Inc. (AIM) announced on Wednesday a significant increase—15-fold—in the incidence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) among patients who have been infected with SARS-CoV-2.
According to findings from the RECOVER-Adult study, 73 out of 4,515 post-COVID patients were diagnosed with ME/CFS at least six months after infection. This equates to a prevalence rate of 4.5 percent, which is nearly eight times higher than that of uninfected participants. Published in the Journal of General Internal Medicine, the study highlighted that the prevalence of ME/CFS is five times greater than pre-pandemic levels, underscoring the substantial and enduring impact of COVID-19 on public health.
As of now, shares of AIM ImmunoTech are trading at $0.22, reflecting a 2.60 percent increase on the New York Stock Exchange American.
